ClinicalTrials.gg
RecruitingNCT06494514Updated Jul 10, 2024

NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer

An interventional study of nal-IRI+Oxaliplatin+5-FU/LV+PD-1 and Gemcitabine + albumin-paclitaxel+PD-1 in Locally Advanced Pancreatic Cancer, sponsored by Du Juan. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-10.

Sponsored by Du Juan · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Apr 2024, registered Jul 2024).
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms — 10 open to participants now, 12 under way, none of them phase 3. irinotecan sucrosofate · Pancreatic Neoplasms.

Planned enrollment
22nd of 23
40 · median 64
Started
2024
with 6 others
No phase
2 of 23
2 open now
Primary completion
2027-04
later than 9 of 11 live
Registered
19th of 23
by date
Lead sponsor
1 of 23
Du Juan

Among the 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms, this one is the 22nd largest by planned enrollment, is one of 7 that started in 2024, is one of 2 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 19th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

10 of the 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About irinotecan sucrosofate

irinotecan sucrosofate: first FDA approval 2015 (ONIVYDE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of NALIRINOX combined with PD-1 synchronous sequential SBRT or AG combined with PD-1 synchronous sequential SBRT as first line systematical therapy in patients with ocally advanced pancreatic cancer.

03

Conditions studied

  • Locally Advanced Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed pancreatic cancer;
  2. performance no more than 2;
  3. Radiographically assessed as locally advanced pancreatic cancer according to NCCN guidelines;
  4. No previous anti-tumor therapy;
  5. Able and willing to provide a written ;

Exclusion criteria

Exclusion Criteria:

    1. Prior anti-tumor therapy of any kind; 2. Severe infection (>NCI CTC grade 2); 3.Patients with disease or immune deficiency who are treated with drugs; 4.Patients with bleeding tendency; 5. Pregnant or lactating women.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    NALIRINOX combined with PD-1 synchronous sequential SBRT

    Nal-IRI+Oxaliplatin+5-FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, 6-8 cycles. SBRT is performed during the third cycle.

    Drug: nal-IRI+Oxaliplatin+5-FU/LV+PD-1 · Drug: Gemcitabine + albumin-paclitaxel+PD-1

  • Experimental
    AG combined with PD-1 synchronous sequential SBRT

    Gemcitabine + albumin-paclitaxel +PD-1, these drugs are given on d1, d8, 21 days as one cycle, 6-8 cycles. SBRT is performed during the third cycle.

    Drug: nal-IRI+Oxaliplatin+5-FU/LV+PD-1 · Drug: Gemcitabine + albumin-paclitaxel+PD-1

Interventions

06

What researchers measure

Primary outcomes

  1. mPFS

    Time from randomization to disease progression and/or death.

    Time frame: Up to 12 months

Secondary outcomes

  1. mOS

    Time from randomization to death

    Time frame: Up to 24 months

  2. ORR

    According to RECIST version 1.1, the proportion of patients who achieved remission (PR+CR) after treatment and maintained the minimum time-frame requirement.

    Time frame: Up to 12 months

  3. DCR

    According to RECIST version 1.1, the proportion of patients who achieved remission (PR+CR) and stable lesion (SD) after treatment and maintained the minimum time-frame requirements.

    Time frame: Up to 12 months

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2027, 36 months after the start.

Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 36 months is below that.

Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2024
First posted
Jul 10, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Jul 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06494514
Lead sponsor
Du Juan
Responsible party
Du Juan (chief physician choice, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School) — Sponsor-investigator
First posted
Jul 10, 2024
Start date
Apr 1, 2024
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Jul 10, 2024

Study contacts

Juan Du, M.D. Ph.D
Contact
dujunglyy@163.com
+86-025-83106666
Juan Du
Contact
dujunglyy@163.com
02583106666 ext. +86
Juan Du
principal investigator · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Min Tu
study director · The First Affiliated Hospital with Nanjing Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irinotecan sucrosofate · Oxaliplatin · Fluorouracil · Immune checkpoint inhibitors

Start the discussion